Lurbinectedin is a chemotherapy drug that has been shown to have anti-tumor activity in a variety of cancers. It works by inhibiting the transcription of DNA, which leads to cell death [1]. There is some evidence to suggest that lurbinectedin may be able to improve response rates in immunotherapy.

One study found that lurbinectedin can enhance the anti-tumor activity of immune checkpoint inhibitors (ICIs) in preclinical models of cancer. Specifically, the combination of lurbinectedin and ICIs resulted in increased tumor infiltration by T cells, increased production of pro-inflammatory cytokines, and improved tumor control [2]. Another study found that lurbinectedin can increase the expression of major histocompatibility complex class I (MHC-I) on cancer cells, which can make them more visible to the immune system [3].

However, it is important to note that the use of lurbinectedin in combination with immunotherapy is still in the preclinical stage, and more research is needed to determine its safety and efficacy in humans. Additionally, resistance to immunotherapy is a complex issue that may require advanced strategies beyond the use of lurbinectedin.

In conclusion, while there is some evidence to suggest that lurbinectedin may be able to improve response rates in immunotherapy, more research is needed to determine its safety and efficacy in humans. Additionally, the issue of resistance to immunotherapy is complex and may require advanced strategies beyond the use of lurbinectedin [1-3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.targetedonc.com/view/overcoming-resistance-to-immunotherapy-requires-advanced-strategies